A proof-of-concept Phase 2 trial with rosiptor (AQX-1125) in patients with chronic prostatitis/chronic Pelvic Pain Syndrome (CP/CPPS)

Trial Profile

A proof-of-concept Phase 2 trial with rosiptor (AQX-1125) in patients with chronic prostatitis/chronic Pelvic Pain Syndrome (CP/CPPS)

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Pelvic pain; Prostatitis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 11 Aug 2017 New trial record
    • 08 Aug 2017 According to an Aquinox Pharmaceuticals media release, patient enrollment in this trial is expected to commence in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top